retatrutide type 2 diabetes phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA The numbers from Lilly's Phase

Table of Contents What defines non-response to GLP-1 therapy Common causes of poor response Identifying modifiable factors Next-step clinical strategies What Defines Non-Response to GLP-1 Therapy in Practice Patients considered non-responders to GLP-1 therapy typically fail to achieve meaningful reductions in HbA1c or body weight after an adequate trial period

Full-dose GLP-1 therapy focuses on treating obesity and metabolic disease

It shows that members who used the Noom GLP-1 Companion app most frequently achieved greater weight lossand a higher rate of medication program persistencecompared with less-engaged peers

Precision is the name of the game here

Often marketed as a cheaper and easier alternative, these patches are creating waves on social media

Marc Jean-Gilles, DO, FACOG, at Abundant Life Healthcare to determine if GLP-1 medications are right for you